Evotec (EVT) Aperçu de l'action
Evotec SE est un partenaire de l'industrie pharmaceutique et biotechnologique dans le monde entier pour la découverte et le développement de médicaments. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
EVT Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Evotec SE Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | €3.45 |
| Plus haut sur 52 semaines | €7.30 |
| Plus bas sur 52 semaines | €3.18 |
| Bêta | 1.26 |
| Variation sur 1 mois | 0.17% |
| Variation sur 3 mois | -27.30% |
| Variation sur 1 an | -45.46% |
| Variation sur 3 ans | -82.67% |
| Variation sur 5 ans | -92.13% |
| Évolution depuis l'introduction en bourse | -78.12% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 04
EVT: INDiGO Platform And 2026 Guidance Will Drive Future Upside
Analysts have adjusted their price target on Evotec to €4.90 from €6.83, reflecting updated assumptions on fair value, discount rate, revenue, profit margin and future P/E expectations. What’s in the News for Evotec Niagen Bioscience selected Evotec as the contract research organization to support advancement of its oral small molecule NB4168 for Ataxia Telangiectasia, with Evotec providing pharmacokinetic and pharmacodynamic studies plus bioanalytical method validation in collaboration with NAD Pharmaceuticals.
Mise à jour du récit • Jul 21
EVT: Guidance Reset And Manufacturing Rollout Will Likely Constrain Future Re rating
Analysts have lowered their price target on Evotec, citing a shift to a more conservative fair value estimate, along with changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E, which together point to a reduced implied equity value in € terms. What’s in the News for Evotec Evotec reported preliminary unaudited H1 2026 figures, with Group revenues of about €300.1 million and an adjusted Group EBITDA loss of about €42.7 million, highlighting solid cash resources of about €465.6 million as of June 30, 2026.Recent updates
Mise à jour du récit • Aug 04
EVT: INDiGO Platform And 2026 Guidance Will Drive Future Upside
Analysts have adjusted their price target on Evotec to €4.90 from €6.83, reflecting updated assumptions on fair value, discount rate, revenue, profit margin and future P/E expectations. What’s in the News for Evotec Niagen Bioscience selected Evotec as the contract research organization to support advancement of its oral small molecule NB4168 for Ataxia Telangiectasia, with Evotec providing pharmacokinetic and pharmacodynamic studies plus bioanalytical method validation in collaboration with NAD Pharmaceuticals.Mise à jour du récit • Jul 21
EVT: Guidance Reset And Manufacturing Rollout Will Likely Constrain Future Re rating
Analysts have lowered their price target on Evotec, citing a shift to a more conservative fair value estimate, along with changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E, which together point to a reduced implied equity value in € terms. What’s in the News for Evotec Evotec reported preliminary unaudited H1 2026 figures, with Group revenues of about €300.1 million and an adjusted Group EBITDA loss of about €42.7 million, highlighting solid cash resources of about €465.6 million as of June 30, 2026.Mise à jour du récit • Jul 07
EVT: Rich P/E Will Likely Outweigh Benefits Of New Manufacturing Initiative
Analysts have raised their fair value estimate for Evotec from €4.0 to €4.5. They attribute this change to slightly adjusted discount rate assumptions, modestly higher expectations for revenue growth and profit margins, and a higher future P/E multiple in their updated models. What’s in the News for Evotec Evotec, through its Just – Evotec Biologics unit, launched J.TRAIN, a turnkey offering that lets biopharmaceutical companies deploy its proprietary continuous biologics manufacturing technology directly inside their own facilities, combining modular cleanrooms, industry-standard equipment and cGMP-compliant process automation.Mise à jour du récit • Jun 23
EVT: Rich P/E Expectations Will Likely Outweigh Alliance And Governance Progress
Analysts have revised their fair value estimate for Evotec to €4.0 from €4.4, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Evotec Evotec and Almirall nominated a small molecule preclinical development candidate in medical dermatology from their multi target drug discovery alliance, focused on immune mediated inflammatory skin diseases with high unmet medical need.
Mise à jour du récit • Jun 06
EVT: AI And Royalty Pipeline Will Support Future Earnings Upside
Analysts have slightly adjusted their outlook on Evotec, keeping the fair value estimate steady at €10.00 while fine tuning assumptions around discount rate, revenue growth, profit margin, and future P/E to reflect updated expectations for the business. What's in the News Evotec appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, to lead the integration of computational science and data driven decision making across its R&D operations, positioning AI and in silico capabilities as key parts of the company’s commercial offering.Mise à jour du récit • May 23
EVT: Future Milestone And Royalty Stream Will Support Earnings Upside
Analysts have trimmed their price target on Evotec from €10.40 to €10.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that now sit slightly below prior estimates but remain within a similar range. What's in the News Evotec and Almirall nominated a small molecule preclinical development candidate for immune mediated inflammatory skin diseases, using Evotec’s AI/ML supported discovery and preclinical platforms, with potential success based milestones of up to €230 million per program plus high single digit royalties on net sales (Key Developments).Mise à jour du récit • May 04
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).Mise à jour du récit • Apr 19
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.Mise à jour du récit • Apr 05
EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside
Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).Mise à jour du récit • Mar 21
EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions
Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.Mise à jour du récit • Mar 07
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.Mise à jour du récit • Feb 20
EVT: Kidney Disease Milestone Prospects Will Support Future Upside
Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.Mise à jour du récit • Feb 06
EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside
Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).Mise à jour du récit • Jan 22
EVT: Milestone Progress And Share Buybacks Will Support Future Upside
Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.Mise à jour du récit • Jan 07
EVT: Milestone Payment And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.Mise à jour du récit • Dec 17
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.Mise à jour du récit • Dec 03
EVT: Share Buybacks And Milestone Payment Will Support Future Upside
Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.Mise à jour du récit • Aug 21
Large Pharma Partnerships And AI Platforms Will Open New Markets
The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
Nouveau récit • Apr 30
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.Article d’analyse • Nov 10
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...Article d’analyse • Nov 05
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...Article d’analyse • Aug 17
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...Article d’analyse • Aug 08
Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...Article d’analyse • Aug 03
We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendement pour les actionnaires
| EVT | DE Life Sciences | DE Marché | |
|---|---|---|---|
| 7D | -5.7% | 1.4% | 0.2% |
| 1Y | -45.5% | 6.7% | 3.6% |
Rendement vs Industrie: EVT a sous-performé le secteur German Life Sciences qui a rapporté 6.7 % au cours de l'année écoulée.
Rendement vs marché: EVT a sous-performé le marché German qui a rapporté 3.6 % au cours de l'année écoulée.
Volatilité des prix
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 8.8% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Cours de l'action stable: Le cours de l'action de EVT a été volatil au cours des 3 derniers mois par rapport au marché German.
Volatilité au fil du temps: La volatilité hebdomadaire de EVT ( 9% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de German.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1993 | 4,461 | Christian Wojczewski | www.evotec.com |
Evotec SE est un partenaire de l'industrie pharmaceutique et biotechnologique dans le monde entier pour la découverte et le développement de médicaments. Elle opère dans deux segments, Shared R&D et Just Evotec Biologics. La société développe des produits pharmaceutiques dans divers domaines thérapeutiques, tels que l'oncologie, les maladies auto-immunes, le cancer, le diabète, l'insuffisance cardiaque, la fibrose, l'immunologie, la douleur et l'inflammation, les maladies infectieuses, rénales, hépatiques, rares, respiratoires, fibrotiques et métaboliques, le système nerveux central (SNC) et les troubles cardio-métaboliques, ainsi que la santé animale et la santé des femmes.
Evotec SE Résumé des fondamentaux
| EVT statistiques fondamentales | |
|---|---|
| Capitalisation boursière | €612.52m |
| Bénéfices(TTM) | -€197.05m |
| Recettes(TTM) | €717.28m |
0.9x
Ratio P/S-3.1x
Ratio P/ELe site EVT est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| EVT compte de résultat (TTM) | |
|---|---|
| Recettes | €717.28m |
| Coût des recettes | €656.57m |
| Marge brute | €60.71m |
| Autres dépenses | €257.76m |
| Les revenus | -€197.05m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
Nov 05, 2026
| Résultat par action (EPS) | -1.11 |
| Marge brute | 8.46% |
| Marge bénéficiaire nette | -27.47% |
| Ratio dettes/capitaux propres | 47.7% |
Quelles ont été les performances à long terme de EVT?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/17 13:33 |
| Cours de l'action en fin de journée | 2026/08/14 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Evotec SE est couverte par 24 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Christian Ehmann | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |